CHRNA7 and post-traumatic stress disorder: For example, Bionomics’ BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, failed to significantly improve symptoms compared to placebo in a Phase II PTSD trial because of insufficient exposure (bioavailability)199.